Physician profile
Husam E Eddin
NPI 1629082607
$4,782.60
in general payments reported to CMS, 2019-2025
36 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $468 · 2021: $821 · 2022: $700 · 2023: $817 · 2024: $609 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.71 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $804.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $612.53 | 2022-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $424.10 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $396.55 | 2022-2025 | Ongentys |
| Astellas Pharma US INC | $328.38 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $290.67 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $169.56 | 2022-2024 | Austedo Xr |
| Madrigal Pharmaceuticals | $141.60 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $134.97 | 2023 | Gemtesa |
| Pfizer INC. | $125.34 | 2021-2025 | |
| Neurelis, INC. | $125.03 | 2022-2023 | Valtoco |
| Ultragenyx Pharmaceutical INC. | $121.64 | 2020-2021 | |
| Leo Pharma INC. | $108.20 | 2025 | Anzupgo |
| Vanda Pharmaceuticals INC. | $98.13 | 2020-2021 | |
| Lilly USA, LLC | $87.95 | 2020-2024 | Mounjaro, Zepbound |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Eddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.